E. Dogan Et Al. , "Efficacy and Tolerability of First-Line Anti-eGFR and Anti-VEGF Therapy in Elderly Patients with Ras-Wild Metastatic Colon Cancer," ISTANBUL MEDICAL JOURNAL , no.3, pp.181-184, 2024
Dogan, E. Et Al. 2024. Efficacy and Tolerability of First-Line Anti-eGFR and Anti-VEGF Therapy in Elderly Patients with Ras-Wild Metastatic Colon Cancer. ISTANBUL MEDICAL JOURNAL , no.3 , 181-184.
Dogan, E., Firat, S. T., ESER, M., BOZKURT, O., İNANÇ, M., & ÖZKAN, M., (2024). Efficacy and Tolerability of First-Line Anti-eGFR and Anti-VEGF Therapy in Elderly Patients with Ras-Wild Metastatic Colon Cancer. ISTANBUL MEDICAL JOURNAL , no.3, 181-184.
Dogan, Ender Et Al. "Efficacy and Tolerability of First-Line Anti-eGFR and Anti-VEGF Therapy in Elderly Patients with Ras-Wild Metastatic Colon Cancer," ISTANBUL MEDICAL JOURNAL , no.3, 181-184, 2024
Dogan, Ender Et Al. "Efficacy and Tolerability of First-Line Anti-eGFR and Anti-VEGF Therapy in Elderly Patients with Ras-Wild Metastatic Colon Cancer." ISTANBUL MEDICAL JOURNAL , no.3, pp.181-184, 2024
Dogan, E. Et Al. (2024) . "Efficacy and Tolerability of First-Line Anti-eGFR and Anti-VEGF Therapy in Elderly Patients with Ras-Wild Metastatic Colon Cancer." ISTANBUL MEDICAL JOURNAL , no.3, pp.181-184.
@article{article, author={Ender Dogan Et Al. }, title={Efficacy and Tolerability of First-Line Anti-eGFR and Anti-VEGF Therapy in Elderly Patients with Ras-Wild Metastatic Colon Cancer}, journal={ISTANBUL MEDICAL JOURNAL}, year=2024, pages={181-184} }